COMPANY
Exelixis
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior Staff IT Product Lead - Microsoft 365 Enterprise | Alameda, CA | Oct 22, 2026 | Oct 6, 2026 |
| Corporate Counsel, Contracts | Alameda, CA | Oct 20, 2026 | Oct 21, 2026 |
| Senior Staff Engineer - Cloud Platform, Enterprise Integration & Application Architect | Alameda, CA | Oct 19, 2026 | Oct 6, 2026 |
| Senior Oncology Account Manager - (Birmingham, AL | Remote) | Remote | Oct 19, 2026 | Oct 5, 2026 |
| Executive Medical Director, Pharmacovigilance Risk Management (PVRM) | Remote | Oct 19, 2026 | Oct 7, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 3 trial (NCT07620574, actual start Jul 30, 2026); 13 clinical-operations roles open. ClinicalTrials.gov NCT07620574 (Jul 30, 2026)
Evidence (1 event)
- Jul 30, 2026 · ClinicalTrials.gov NCT07620574
leadSponsor.name='Exelixis'; phases=['PHASE3']; overallStatus=ENROLLING_BY_INVITATION; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-06-02; briefTitle='Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study'
- Jul 30, 2026 · ClinicalTrials.gov NCT07620574
Timeline
- Trial start Phase 2: Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) source ↗
- Board tracked Radar started tracking this company’s job board (63 open jobs at last check). source ↗
- Trial start Phase 1: Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors source ↗
- Trial start Phase 3: Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease source ↗
- Trial start Phase 3: Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study source ↗
- Trial start Phase 2: A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma source ↗
- FDA FDA New indication / efficacy supplement: CABOMETYX (cabozantinib s-malate) — NDA208692/18, Sep 10, 2025. Applicant at approval: Exelixis, Inc. source ↗
- Trial start Phase 1: A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors source ↗
- Trial start Phase 2/Phase 3: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors source ↗
- Trial start Phase 1: Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) source ↗
- Trial start Phase 1: A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors source ↗
- FDA FDA New indication / efficacy supplement: CABOMETYX (cabozantinib s-malate) — NDA208692/17, Mar 26, 2025. Applicant at approval: Exelixis, Inc. source ↗
- Trial start Phase 1: A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors source ↗
- Trial start Phase 1: Study of XB010 in Subjects With Solid Tumors source ↗
- Trial start Phase 2/Phase 3: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma source ↗
- Trial start 1: A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors source ↗
- Trial start Phase 1: Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) source ↗
- Trial start Phase 3: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma source ↗
- Trial start Phase 3: Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer source ↗
- Trial start Phase 1: Study of XL114 in Subjects With Non-Hodgkin's Lymphoma source ↗
- Trial start Phase 1: Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors source ↗
- Trial start Phase 1: Study of XB002 in Subjects With Solid Tumors (JEWEL-101) source ↗
- Trial start Phase 1: Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) source ↗
- Trial start Phase 3: Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC source ↗
- Trial start Phase 3: Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma source ↗
Upcoming milestones
- Nov 23, 2026 (ESTIMATED) · Phase 1 · Study of XB010 in Subjects With Solid Tumors · NCT06545331
- Dec 15, 2026 (ESTIMATED) · Phase 3 · Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma · NCT05678673
- Jan 31, 2027 (ESTIMATED) · Phase 1 · Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors · NCT05176483
- May 31, 2027 (ESTIMATED) · Phase 1 · A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors · NCT06952010
- 2027-11 (ESTIMATED) · Phase 1 · A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors · NCT07123103
- Feb 29, 2028 (ESTIMATED) · Phase 2 · A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma · NCT07428616
- Jun 15, 2028 (ESTIMATED) · Phase 2 · Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) · NCT07845786
- Jul 31, 2028 (ESTIMATED) · Phase 1 · Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors · NCT07773454
Open jobs 63
Clinical trials (lead sponsor) Showing 50 of 57
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07428616 | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma | Phase 2 | Recruiting | May 21, 2026 | Feb 29, 2028 (estimated) |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Active, not recruiting | Sep 5, 2017 | Feb 21, 2023 (actual) |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | Phase 1 | Recruiting | Dec 14, 2021 | Jan 31, 2027 (estimated) |
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/Phase 3 | Recruiting | Jul 21, 2025 | Jun 30, 2029 (estimated) |
| NCT07845786 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Dec 15, 2026 | Jun 15, 2028 (estimated) |
| NCT07750158 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease | Phase 3 | Recruiting | Aug 25, 2026 | Apr 5, 2030 (estimated) |
| NCT07773454 | Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors | Phase 1 | Not yet recruiting | Sep 30, 2026 | Jul 31, 2028 (estimated) |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | Phase 3 | Enrolling by invitation | Jul 30, 2026 | May 31, 2030 (estimated) |
| NCT05678673 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active, not recruiting | Jan 1, 2023 | Dec 15, 2026 (estimated) |
| NCT05425940 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer | Phase 3 | Active, not recruiting | Sep 7, 2022 | Jun 16, 2026 (actual) |
| NCT06952010 | A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | May 1, 2025 | May 31, 2027 (estimated) |
| NCT06545331 | Study of XB010 in Subjects With Solid Tumors | Phase 1 | Recruiting | Aug 6, 2024 | Nov 23, 2026 (estimated) |
| NCT01068782 | Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse | Phase 2 | Terminated | 2010-04 | 2011-05 (actual) |
| NCT07123103 | A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Aug 18, 2025 | 2027-11 (estimated) |
| NCT00596648 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) | Phase 1/Phase 2 | Completed | Feb 12, 2008 | Aug 2, 2012 (actual) |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | Phase 2 | Terminated | 2014-02 | 2014-11 (actual) |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | Phase 3 | Active, not recruiting | Oct 19, 2020 | Apr 19, 2024 (actual) |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | Phase 3 | Active, not recruiting | Jun 10, 2018 | Nov 30, 2021 (actual) |
| NCT03690388 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | Phase 3 | Active, not recruiting | Oct 5, 2018 | Aug 19, 2020 (actual) |
| NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | Phase 3 | Active, not recruiting | Jun 25, 2019 | Jan 31, 2022 (actual) |
| NCT05932862 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | 1 | Recruiting | Apr 3, 2024 | Jan 3, 2029 (estimated) |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer | Phase 4 | Active, not recruiting | Feb 25, 2015 | Jul 15, 2020 (actual) |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2/Phase 3 | Active, not recruiting | Jun 7, 2024 | 2028-08 (estimated) |
| NCT06630247 | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Terminated | Oct 17, 2024 | May 7, 2025 (actual) |
| NCT06962332 | Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) | Phase 1 | Recruiting | May 13, 2025 | 2025-12 (estimated) |
| NCT06191796 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) | Phase 1 | Terminated | Jan 25, 2024 | May 12, 2025 (actual) |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Phase 1 | Completed | Jun 7, 2021 | Mar 10, 2025 (actual) |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | Phase 1 | Active, not recruiting | Mar 20, 2019 | Aug 31, 2026 (estimated) |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Phase 1 | Terminated | Feb 10, 2021 | May 2, 2024 (actual) |
| NCT00940225 | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | Phase 2 | Completed | 2009-09 | 2013-05 (actual) |
| NCT00704288 | Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme | Phase 2 | Completed | 2008-05 | 2012-06 (actual) |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Phase 1 | Terminated | Apr 12, 2022 | Nov 1, 2022 (actual) |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Phase 3 | Completed | Sep 26, 2013 | Oct 16, 2017 (actual) |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | Phase 3 | Completed | 2013-06 | May 22, 2015 (actual) |
| NCT00704730 | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer | Phase 3 | Completed | 2008-06 | 2011-10 (actual) |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | Phase 3 | Terminated | 2012-03 | 2014-10 (actual) |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 | Phase 3 | Completed | 2012-07 | 2014-09 (actual) |
| NCT00464113 | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia | Phase 1 | Terminated | 2007-05 | 2010-12 (actual) |
| NCT00475917 | A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies | Phase 1 | Terminated | 2007-05 | 2008-12 (actual) |
| NCT00595829 | A Phase 1 Study of XL019 in Adults With Polycythemia Vera | 1 | Terminated | 2007-12 | 2009-02 (actual) |
| NCT00526838 | Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies | Phase 1 | Terminated | 2007-09 | 2010-12 (actual) |
| NCT00796484 | Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors | Phase 1 | Terminated | 2008-11 | 2010-11 (actual) |
| NCT00704392 | Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors | Phase 1 | Withdrawn | 2008-06 | 2009-12 (estimated) |
| NCT01553656 | Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer | Phase 1 | Completed | 2011-02 | 2015-05 (actual) |
| NCT00960492 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | Phase 1 | Completed | 2009-09 | 2012-11 (actual) |
| NCT01493869 | Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects | Phase 1 | Completed | 2011-09 | 2014-05 (actual) |
| NCT01761773 | A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function | Phase 1 | Completed | 2012-12 | 2013-04 (actual) |
| NCT01100619 | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors | Phase 1 | Completed | 2010-04 | 2012-08 (actual) |
| NCT00570635 | A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib | 2 | Completed | 2007-12 | 2009-05 (actual) |
| NCT00215605 | Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies | Phase 1 | Completed | 2005-09 | 2011-04 (actual) |
FDA records (last 2 years)
- FDA New indication / efficacy supplement: CABOMETYX (cabozantinib s-malate) — NDA208692/18, Sep 10, 2025. Applicant at approval: Exelixis, Inc. source ↗
- FDA New indication / efficacy supplement: CABOMETYX (cabozantinib s-malate) — NDA208692/17, Mar 26, 2025. Applicant at approval: Exelixis, Inc. source ↗
Raises and investors new
- InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗